Integrated Delivery Platform Orbit Biomedical offers an integrated platform that combines high quality manufacturing with a precise sub-retinal surgical delivery system. This end-to-end capability helps biotech partners de-risk development and accelerate timelines for retinal gene therapies. Business development opportunities include co development, licensing, or white label access to the platform and manufacturing capacity.

Surgeon Training Advantage Surgeon training is a core differentiator for Orbit Biomedical, enabling standardized delivery across sites. This creates a compelling value proposition for CROs, CMOs, and gene therapy developers seeking scalable surgical solutions. Potential engagements include training programs, on-site capability building, and strategic partnerships to standardize procedures across clinical trials.

Global Footprint Operating in Philadelphia and Stevenage provides US and UK access, regulatory familiarity, and access to diverse clinical networks. This footprint enables cross-border collaborations, joint ventures, and trials aligned with FDA and MHRA pathways. BD actions include pursuing co development deals with global retinal gene therapy programs and leveraging UK NHS networks for site access.

Retinal Partner Target Target customers are retinal gene therapy developers that need end-to-end delivery and manufacturing capabilities. Orbit Biomedical can serve as a specialized partner for early stage biotech firms seeking to scale surgical delivery and clinical manufacturing without building in-house facilities. Outreach should focus on small to mid-size gene therapy startups, contract research collaborations, and licensing or sponsored trial opportunities.

Clinical Stage Readiness Clinical-stage readiness positions Orbit Biomedical as a potential partner for programs needing ready access to surgical delivery and manufacturing. With a small team and modest current revenue, the company could pursue platform licensing, manufacturing partnerships, or service engagements to monetize its integrated platform. Priorities include identifying retinal gene therapy programs requiring reliable, scalable delivery and training support.